Corrigendum: Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance

Front Pharmacol. 2022 Apr 28:13:890886. doi: 10.3389/fphar.2022.890886. eCollection 2022.

Xixi Lin¹, Yongliang Jia^{2

3}, Xinwei Dong^{2

3}, Jian Shen^{2

3}, Yachao Jin³, Yanyou Li⁴, Fang Wang⁵, Eitan Anenberg¹, Jiancang Zhou⁶, Jianping Zhu⁶, Xiaoping Chen⁴, Qiangmin Xie^{1

2}, Yicheng Xie¹

¹ Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
² Zhejiang Respiratory Drugs Research Laboratory of Food and Drug Administration of China, Zhejiang University School of Medicine, Hangzhou, China.
³ Breath Smooth Biotech Hangzhou Co., LTD, Hangzhou, China.
⁴ Beijing Shuobai Pharmaceutical Co., LTD, Beijing, China.
⁵ Joinn Laboratories, BAD, Beijing, China.
⁶ Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Abstract

[This corrects the article DOI: 10.3389/fphar.2019.00982.].

Keywords: Platinum complex; ROS/p53 pathway; Water solubility; cisplatin resistance; lung cancer.